West Pharmaceutical Services Announces Upcoming Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy WST?
Source: Newsfilter
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Barclays Global Healthcare Conference on March 10, 2026, and the KBCM Healthcare Forum on March 18, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's market image.
- Webcast Availability: The company will provide live webcasts of these events on its website's Investors section, with replays available for approximately 90 days, a move that not only enhances transparency but also offers convenience for investors who cannot attend live, thereby improving investor relations.
- Company Background: West Pharmaceutical Services is a leading provider of injectable solutions, generating $3.07 billion in net sales for fiscal year 2025, demonstrating its strong market position and growth potential, which attracts trust and collaboration from numerous drug developers.
- Global Operational Scale: With over 10,000 employees across 50 locations, including 25 manufacturing facilities, the company delivers over 41 billion components and devices annually, ensuring efficient production capabilities and reliable support for its customers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 243.350
Low
285.00
Averages
348.70
High
375.00
Current: 243.350
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Analysis of Risks in Overvalued Stocks
- Keysight Stock Risks: Keysight (NYSE:KEYS) has shown only 3.1% annual revenue growth over the past two years, which is below industry peers, and declining earnings per share raises investor concerns; with a current stock price of $286.50 and a forward P/E of 31.4x, it indicates significant overvaluation risks.
- Moog Stock Caution: Moog (NYSE:MOG.A) has experienced only 4.9% annual revenue growth over the last five years, while increasing capital intensity has led to a 6.6 percentage point drop in free cash flow margin; trading at $308.25 per share with a forward P/E of 32.9x reflects management's struggles in finding profitable growth opportunities.
- West Pharmaceutical Services Risks: West Pharmaceutical Services (NYSE:WST) has seen a mere 2.1% annual revenue growth over the last two years, with a 6.7 percentage point decrease in adjusted operating margin, and a stock price of $238.92 implies a forward P/E of 29.9x, indicating weakening profitability.
- Identifying Market Opportunities: Despite the risks associated with these overvalued stocks, StockStory's list of high-quality stocks demonstrates robust revenue growth and cash flow, assisting investors in identifying potential market winners.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
Market Capitalization Comparison: West Pharmaceutical vs. Viatris
- Market Cap Overview: West Pharmaceutical (WST) has a market capitalization of $17.16 billion compared to Viatris (VTRS) at $16.07 billion, highlighting the relative size difference that influences investor choices and capital flows.
- Investor Misconception: Many novice investors mistakenly believe that a higher stock price indicates greater company value, but market capitalization provides a more accurate comparison of company worth, aiding investors in making informed decisions.
- Market Impact: Market capitalization determines a company's size tier among peers, influencing which mutual funds and ETFs are willing to hold these stocks, particularly as large funds tend to favor companies with market caps exceeding $10 billion.
- Stock Performance: At Thursday's close, WST's stock fell approximately 3%, while VTRS declined about 1.2%, reflecting differing market reactions to the short-term performance of the two companies.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Analysis of Risks in Overvalued Stocks
- Keysight Stock Risks: Keysight (NYSE:KEYS) has shown only 3.1% annual revenue growth over the past two years, which is below industry peers, and declining earnings per share raises investor concerns; with a current stock price of $286.50 and a forward P/E of 31.4x, it indicates significant overvaluation risks.
- Moog Stock Caution: Moog (NYSE:MOG.A) has experienced only 4.9% annual revenue growth over the last five years, while increasing capital intensity has led to a 6.6 percentage point drop in free cash flow margin; trading at $308.25 per share with a forward P/E of 32.9x reflects management's struggles in finding profitable growth opportunities.
- West Pharmaceutical Services Risks: West Pharmaceutical Services (NYSE:WST) has seen a mere 2.1% annual revenue growth over the last two years, with a 6.7 percentage point decrease in adjusted operating margin, and a stock price of $238.92 implies a forward P/E of 29.9x, indicating weakening profitability.
- Identifying Market Opportunities: Despite the risks associated with these overvalued stocks, StockStory's list of high-quality stocks demonstrates robust revenue growth and cash flow, assisting investors in identifying potential market winners.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
Market Capitalization Comparison: West Pharmaceutical vs. Viatris
- Market Cap Overview: West Pharmaceutical (WST) has a market capitalization of $17.16 billion compared to Viatris (VTRS) at $16.07 billion, highlighting the relative size difference that influences investor choices and capital flows.
- Investor Misconception: Many novice investors mistakenly believe that a higher stock price indicates greater company value, but market capitalization provides a more accurate comparison of company worth, aiding investors in making informed decisions.
- Market Impact: Market capitalization determines a company's size tier among peers, influencing which mutual funds and ETFs are willing to hold these stocks, particularly as large funds tend to favor companies with market caps exceeding $10 billion.
- Stock Performance: At Thursday's close, WST's stock fell approximately 3%, while VTRS declined about 1.2%, reflecting differing market reactions to the short-term performance of the two companies.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
